Senior Division Manager (East Central Region)

Remote

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

A Bachelor's degree is required, with an advanced degree preferred. Candidates must have over 10 years of biotech/pharma sales experience, including at least 3 years in a sales leadership role. Prior cross-functional experience and a proven track record in hematology/oncology and/or cell therapy markets are necessary. Strong inspirational leadership, clear communication, and advanced coaching and team development skills are essential, along with an innovative and strategic mindset for building and implementing actionable account plans.

Responsibilities

The Senior Division Manager will build, lead, and develop a team of seven sales professionals for the launch and expansion of anitocabtagene autoleucel. Responsibilities include attracting, retaining, and developing top talent, onboarding and training the team to exceed launch expectations, and leading the team to meet and exceed sales goals. The role involves analyzing market trends, developing divisional sales plans, engaging with key customers to build relationships, collaborating with partner Kite Pharma, and attending/leading commercial activities at scientific meetings, while ensuring compliance with all regulatory and legal requirements.

Skills

Sales Strategy

Team Leadership

CAR T

Biotechnology

Oncology

Multiple Myeloma

Sales Management

Launch Strategy

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free